This HTML5 document contains 61 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n4http://linked.opendata.cz/resource/drugbank/company/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00517/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00517/identifier/kegg-compound/
n8http://bio2rdf.org/drugbank:
n13http://linked.opendata.cz/resource/drugbank/drug/DB00517/identifier/kegg-drug/
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00517/identifier/drugbank/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00517/identifier/chebi/

Statements

Subject Item
n2:DB00517
rdf:type
n3:Drug
n3:description
Anisotropine methylbromide is a quaternary ammonium compound. Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. Depending on the dose, anisotropine methylbromide may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder. In general, smaller doses of anisotropine methylbromide inhibit salivary and bronchial secretions, sweating, and accommodation; cause dilatation of the pupil; and increase the heart rate. Larger doses are required to decrease motility of the gastrointestinal and urinary tracts and to inhibit gastric acid secretion.
n3:group
approved
n3:halfLife
Not Known
n3:indication
For use in conjunction with antacids or histamine H<sub>2</sub>-receptor antagonists in the treatment of peptic ulcer, to reduce further gastric acid secretion and delay gastric emptying.
n3:manufacturer
n4:271B6418-363D-11E5-9242-09173F13E4C5 n4:271B6419-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00517 n8:DB00517
dcterms:title
Anisotropine Methylbromide
adms:identifier
n10:PA164754880 n12:C06830 n13:D00232 n14:2739 n15:DB00517
n3:mechanismOfAction
Quaternary ammonium compounds such as anisotropine methylbromide inhibit the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These postganglionic receptor sites are present in the autonomic effector cells of the smooth muscle, cardiac muscle, sinoatrial and atrioventricular nodes, and exocrine glands.
n3:synonym
Octatropini methylbromidum Anisotropine methylbromide Endo-8,8-dimethyl-3-((1-oxo-2-propylpentyl)oxy)-8-azoniabicyclo(3.2.1)octane bromide 8-Methyl-3-(2-propylpentanoyloxy)tropinium bromide Octatropine methylbromide Methylbromure d'octatropine 8-Methyltropinium bromide 2-propylpentanoate Anisotropine methobromide Metilbromuro de octatropina 8-Methyltropinium bromide 2-propylvalerate Methyloctatropine bromide
n3:proteinBinding
Not Known
n3:synthesisReference
Weiner, N. and Gordon, S.M.; US. Patent 2,962,499; November 29,1960; assigned to Endo Laboratories, Inc.
n3:IUPAC-Name
n7:271B641E-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B6424-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B6423-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B6420-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B6421-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B6422-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B6433-363D-11E5-9242-09173F13E4C5 n7:271B641C-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B641A-363D-11E5-9242-09173F13E4C5 n7:271B641D-363D-11E5-9242-09173F13E4C5 n7:271B6435-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B641B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n7:271B642A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B642B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B6425-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B6426-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B6428-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B6427-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B6429-363D-11E5-9242-09173F13E4C5
n3:absorption
Gastrointestinal absorption is poor and irregular. Total absorption after an oral dose is about 10 to 25%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
80-50-2
n3:category
n3:Bioavailability
n7:271B642F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B6431-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B6432-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n7:271B6434-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B642E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B642D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B6430-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B641F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B642C-363D-11E5-9242-09173F13E4C5